A Phase 1 Trial of GEN1119 in Participants With Solid Tumors

NCT07695831 | Not Yet Recruiting Phase 1 DMC

• 2 other identifiers: GCT1119-012026-525610-62
• Study Type: interventional
• Target: 112
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this trial is to learn about the safety and efficacy of GEN1119 when it is used for the treatment of participants with certain types of cancer. The trial has multiple parts. The first part of the trial will test different doses of GEN1119 to find out if it is safe and to determine what are the best doses to use. The second part will further refine this optimal dose. The third part continues to test the safety and how well GEN1119 works in additional participants with specific cancer types and at doses chosen based on the results of the first 2 parts of the trial. For each participant, the trial will last approximately 18 months but this may vary for each individual. This includes a Screening Period of up to 21 days before receiving trial treatment, an estimated 5 months of treatment (the duration of treatment may vary for each participant), and approximately 12.5 months of follow up after trial treatment ends (the duration of follow up may vary for each participant). Participation in the trial will require visits to the site, with more frequent visits during the first 6 weeks of treatment and then less frequent visits afterwards. At site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, computed tomography \[CT\] scans) to monitor whether the treatment is safe and effective. All participants will receive active drug; no one will be given placebo.

Conditions

Solid Tumours

Outcome Measures

Primary Outcomes (3)

• Part 1: Number of Participants with Dose-limiting Toxicities (DLTs)

  21 days

• Part 1 and Part 2: Number of Participants with Adverse Events (AEs)

  Up to approximately 17.5 months

• Part 3: Objective Response Rate (ORR)

  Up to approximately 17.5 months

Secondary Outcomes (7)

• Part 1, Part 2 and Part 3: Plasma Concentration of GEN1119-related Analytes

  Up to approximately 17.5 months

• Part 1, Part 2 and Part 3: Number of Participants with Anti-drug Antibodies (ADAs) Against GEN1119

  Up to approximately 17.5 months

• Part 1 and Part 2: ORR

  Up to approximately 17.5 months

• Part 1, Part 2 and Part 3: Duration of Response (DOR)

  Up to approximately 17.5 months

• Part 1, Part 2 and Part 3: Disease Control Rate (DCR)

  Up to approximately 17.5 months

Study Arms (3)

Dose Escalation (Part 1): GEN1119

EXPERIMENTAL

Participants will receive a number of dose levels (DLs) of GEN1119.

Drug: GEN1119

Dose Refinement (Part 2): GEN1119

EXPERIMENTAL

Participants will be randomized to receive a number of DLs of GEN1119.

Drug: GEN1119

Expansion (Part 3): GEN1119

EXPERIMENTAL

Participants with certain solid tumours will receive GEN1119 at the recommended expansion dose(s) as defined in Parts 1 and/or 2.

Drug: GEN1119

Interventions

GEN1119 DRUG

Administered at certain DLs on specified days.

Dose Escalation (Part 1): GEN1119; Dose Refinement (Part 2): GEN1119; Expansion (Part 3): GEN1119

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Have histologically or cytologically confirmed diagnosis of protocol-specified solid tumours.
• Have progressed on standard of care (SoC) therapy applicable for the tumor type, or for whom there is no available SoC therapy likely to provide clinical benefit, and for whom experimental therapy with GEN1119 may be a suitable option in the opinion of the investigator.
• Have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
• Have acceptable laboratory test results before GEN1119 administration per protocol

You may not qualify if:

• Prior treatment with certain protocol-defined therapy.
• Prior treatment with T-cell engagers, chimeric antigen receptor T-cell (CAR-T-cell) therapies, other protocol defined therapies, or other therapeutic moieties targeting certain protocol-defined molecules.
• Treatment with an anticancer agent within 4 weeks or within 5 half lives of the drug, whichever is shorter, but not within 2 weeks before Cycle 1 Day 1 (C1D1).
• Has clinically significant toxicities from previous anticancer therapies that have not resolved to baseline levels or to Grade 1 or lower, except for anorexia, hyperthyroidism, hypothyroidism, and peripheral neuropathy, which must have recovered to ≤ Grade 2. There is no limitation for alopecia from previous therapies.
• Participant should not have active Hepatitis B infection. Participants with prior infections or chronic infections are allowed if monitored or treated as per local SOC and are negative for hepatitis B virus (HBV) DNA measured viral load.
• Hepatitis C virus (HCV): Known active HCV infection (defined as positive for HCV ribonucleic acid \[RNA\] \[qualitative\]).

Sponsors & Collaborators

• Genmab: lead

Study Officials

• Study Official

  Genmab

  STUDY DIRECTOR

Central Study Contacts

Genmab Trial Information

CONTACT

+4570202728; clinicaltrials@genmab.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Masking Details: Randomization will not be used in Part 1 of this trial. Randomization will be incorporated into Part 2 cohorts and during Part 3 of the trial, randomization will be activated only if at least 2 recommended doses have been advanced from the preceding Parts 1 and/or 2.
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 6, 2026
• First Posted: July 10, 2026
• Study Start: August 1, 2026
• Primary Completion (Estimated): June 1, 2029
• Study Completion (Estimated): June 1, 2029
• Last Updated: July 10, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share